Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Sarcoma, Alveolar Soft Part 1

Interventions

entrectinib 2venetoclax 1trametinib 1tazemetostat 1sodium thiosulfate 1selpercatinib 1ripretinib 1repotrectinib 1pirtobrutinib 1pembrolizumab 1nirogacestat 1larotrectinib 1dabrafenib 1avapritinib 1atezolizumab 1Taxes 1Specimen Handling 1Rituximab 1Restraint, Physical 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × atezolizumab × Sarcoma × Clear all
NCT03141684 2026-06-03

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
63 enrolled 1 FDA
Sarcoma

Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡